Citation Impact
Citing Papers
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
2015
Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors
2017
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
Cancer statistics, 2020
2020 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system
2012
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
2012
A view on drug resistance in cancer
2019 StandoutNature
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
2016
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma
2010
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
2009
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
2017
Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center
2011
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
2018
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer
2011
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
Antitumour actions of interferons: implications for cancer therapy
2016
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
2018
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Colorectal cancer
2019 Standout
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial
2012
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads
2012
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
2011
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
2011
Mechanisms and functional significance of tumour-induced dendritic-cell defects
2004
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Risk assessment for cancer-associated thrombosis: What is the best approach?
2012
Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States
2012
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
2012
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
2011
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
2012
Cancer immunotherapy comes of age
2011 StandoutNature
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
2015
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
2017
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
2016
Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism
2009
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
2018
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
2016
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
2012
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
2009
Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer
2012
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)
2012
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
2011
Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
2016
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
2007
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
2017
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
2015
Risk factors for venous thromboembolic events in cancer patients
2005
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2013
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
2017
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
2004
Works of Mario Mandalà being referenced
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
2014
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
2009
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findings
2008
Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database
2009
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations
2009
Venous thromboembolism and cancer: new issues for an old topic
2003
Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?
2006
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
2013
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
2007
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
2015
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
2011
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
2016
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
2016
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
2018
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
2014
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
2011
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM)
2006
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management
2010
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
2009
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
2014
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
2017
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
2013
Acquired and inherited risk factors for the developing of venous thromboembolism in cancer patients receiving adjuvant chemotherapy: A prospective trial
2009
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
2017
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
2013
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
2018
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
2002
Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon
2013
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).
2013
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
2017
Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action
2009
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’
2011